Synergistic antitumor effects of cMet inhibitor in combination with anti-VEGF in colorectal cancer patient–derived xenograft m
Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patie
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g02.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig2/AS:618753171652608@1524533660275/Correlation-between-tumor-growth-inhibition-and-growth-rate-inhibition-for-xenograft_Q320.jpg)
Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g00.jpg)
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts
![DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12967-019-1785-7/MediaObjects/12967_2019_1785_Fig3_HTML.png)
DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models | Journal of Translational Medicine | Full Text
Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues
![Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-07153-z/MediaObjects/41598_2022_7153_Fig1_HTML.png)
Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment | Scientific Reports
Tumor growth inhibition (TGI)-monotherapy (a) and combination therapy (b). | Download Scientific Diagram
![Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers](https://www.frontiersin.org/files/MyHome%20Article%20Library/793349/793349_Thumb_400.jpg)
Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice - Frontiers
![Characterization of tumor growth inhibition (TGI) data with the PK/PD... | Download Scientific Diagram Characterization of tumor growth inhibition (TGI) data with the PK/PD... | Download Scientific Diagram](https://www.researchgate.net/publication/233418620/figure/fig3/AS:333813650608131@1456598784909/Characterization-of-tumor-growth-inhibition-TGI-data-with-the-PK-PD-Model-a-TGI-data.png)
Characterization of tumor growth inhibition (TGI) data with the PK/PD... | Download Scientific Diagram
![Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram](https://www.researchgate.net/publication/324709939/figure/fig1/AS:618753171664896@1524533660240/Commonly-used-antitumor-efficacy-metrics-Top-panel-T-C-ratio-Middle-panel-TGI-Bottom_Q640.jpg)
Commonly used antitumor efficacy metrics. Top panel: T/C ratio. Middle... | Download Scientific Diagram
![Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram](https://www.researchgate.net/publication/267273025/figure/fig3/AS:295589012099074@1447485320193/Simulation-Tumor-Growth-Profile-of-TGI-Lifespan-Model-Plot-of-tumor-weight-vs-time-The.png)
Simulation Tumor Growth Profile of TGI Lifespan Model. Plot of tumor... | Download Scientific Diagram
![Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12885-016-2455-2/MediaObjects/12885_2016_2455_Fig1_HTML.gif)
Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation | BMC Cancer | Full Text
![Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-12-00975/article_deploy/html/images/pharmaceutics-12-00975-g005.png?1603436374)
Pharmaceutics | Free Full-Text | Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
![Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts](https://www.spandidos-publications.com/article_images/or/33/5/OR-33-05-2135-g08.jpg)